SEC Form 4	
------------	--

## FORM 4

Check this box if no longer subject

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

-	T OF CHANGES IN BENEFICIAL OWN	-	OMB Number: Estimated average bur hours per response:	3235-0287 den 0.5
Filed	oursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	l		1
	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of R	eporting Person(s) to	Issuer

to Section 1	6. Form 4 or Form 5 may continue. See (b).		Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934			Estimated a hours per re	average burden esponse:	0.5
1. Name and Ac Tatsis Our	ddress of Reporting ania	J Person <sup>*</sup>	or Section 30(h) of the Investment Company Act of 1940   2. Issuer Name and Ticker or Trading Symbol   VERTEX PHARMACEUTICALS INC /   MA [ VRTX ]		k all applical Director Officer (g	ole)	rson(s) to Issue 10% Owne Other (spe	er
(Last) C/O VERTE	(First) X PHARMACE	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 02/06/2024		below) EVP, Ch	ief Reg. &	below) Quality Off.	
INCORPOR 50 NORTHE	ATED RN AVENUE		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indi Line) X			ng (Check Appli porting Person	cable
(Street) BOSTON	МА	02210			Form file Person	d by More tha	an One Reportir	١g
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication					
(- 9)	()	× F/	Check this box to indicate that a transaction was made pursuant t satisfy the affirmative defense conditions of Rule 10b5-1(c). See I			n or written pla	an that is intende	j to

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

		oounico / loq	un ou,		poood on,	0. 20.		ennea		
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	02/06/2024		A		6,976 <sup>(1)</sup>	Α	\$ <mark>0</mark>	55,613	D	
Common Stock	02/06/2024		A		7,866 <sup>(2)</sup>	A	\$ <mark>0</mark>	63,479	D	
Common Stock	02/07/2024		A		7,114 <sup>(3)</sup>	Α	\$ <mark>0</mark>	70,593	D	

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

			(0.9.) P	,				optiono, c			ounnoo	7			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Deriv	r osed ) r. 3, 4	6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Titl Amou Secur Unde Deriv Secur 3 and	int of rities rlying ative rity (Instr.	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

#### Explanation of Responses:

1. Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024.

2. Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest in installments beginning on 02/10/2024.

3. Restricted stock unit award that vests in installments beginning on 02/17/2025.

### **Remarks:**

/s/ Christiana Stevenson
--------------------------

Attorney-in-Fact

02/08/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.